Beth Hecht Xeris Biopharma Holdings, Inc. (XERS) insider trading activity

Beth Hecht is Officer of Xeris Biopharma Holdings, Inc.. Currently has a direct ownership of 1.31 Million shares of XERS, which is worth approximately $9.48 Million. The most recent transaction as insider was on Jan 02, 2026, when has been sold 16,667 shares (Common Stock) at a price of $7.43 per share, resulting in proceeds of $123,835. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.31M

3.35% 3M change

3.3% 12M change

Total Value Held $9.48 Million

Beth Hecht Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2026	SELL Open market or private sale	$123,835 $7.43 p/Share	16,667 Reduced 1.26%	1,308,103 Common Stock
Dec 01 2025	SELL Open market or private sale	$116,835 $7.01 p/Share	16,667 Reduced 1.25%	1,320,176 Common Stock
Nov 11 2025	SELL Open market or private sale	$123,335 $7.4 p/Share	16,667 Reduced 1.23%	1,336,843 Common Stock
Mar 20 2025	SELL Open market or private sale	$217,200 $5.43 p/Share	40,000 Reduced 2.87%	1,353,510 Common Stock
Jan 31 2025	SELL Payment of exercise price or tax liability	$513,651 $3.56 p/Share	144,284 Reduced 10.67%	1,208,510 Common Stock
Jan 31 2025	BUY Grant, award, or other acquisition	-	185,000 Added 11.72%	1,393,510 Common Stock
Jan 03 2025	SELL Payment of exercise price or tax liability	$115,660 $3.61 p/Share	32,039 Reduced 2.31%	1,352,794 Common Stock

Jan 31 2024	SELL Payment of exercise price or tax liability	$112,936 $2.46 p/Share	45,909 Reduced 3.22%	1,380,802 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	750,000 Added 32.54%	1,554,968 Common Stock
Jan 29 2024	SELL Payment of exercise price or tax liability	$52,335 $2.66 p/Share	19,675 Reduced 1.36%	1,426,711 Common Stock
Jan 03 2024	SELL Payment of exercise price or tax liability	$75,013 $2.24 p/Share	33,488 Reduced 2.26%	1,446,386 Common Stock
Jan 31 2023	SELL Payment of exercise price or tax liability	$7,172 $1.24 p/Share	5,784 Reduced 0.39%	1,479,874 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	350,000 Added 30.49%	797,758 Common Stock
Jan 29 2023	SELL Payment of exercise price or tax liability	$26,683 $1.26 p/Share	21,177 Reduced 1.41%	1,485,658 Common Stock
Jan 03 2023	SELL Payment of exercise price or tax liability	$37,506 $1.12 p/Share	33,488 Reduced 2.17%	1,506,835 Common Stock
Jan 31 2022	SELL Payment of exercise price or tax liability	$9,385 $2.11 p/Share	4,448 Reduced 0.29%	1,540,323 Common Stock
Jan 29 2022	SELL Payment of exercise price or tax liability	$29,618 $2.11 p/Share	14,037 Reduced 0.9%	1,544,771 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	225,000 Added 34.0%	436,821 Common Stock
Oct 05 2021	BUY Grant, award, or other acquisition	-	206,366 Added 50.0%	206,366 Common Stock

Also insider at

XERS

XERIS PHARMACEUTICALS INC Healthcare

Officer

ITRM

Iterum Therapeutics plc Healthcare

Director

AYTU

AYTU BIOPHARMA, INC Healthcare

Director

Beth Hecht

Officer

Chicago, IL

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells XERS shares.

Notify only if

Value

Insider Trading

Get notified when an Xeris Biopharma Holdings, Inc. insider buys or sells XERS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Xeris Biopharma Holdings, Inc.

Track Activities on XERS

Account